IDEXX Laboratories, Inc. (NASDAQ:IDXX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating) have been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $514.75.

Several analysts have weighed in on the company. Barclays raised their price target on IDEXX Laboratories from $582.00 to $590.00 and gave the company an “overweight” rating in a report on Wednesday, February 8th. JPMorgan Chase & Co. increased their price objective on IDEXX Laboratories from $525.00 to $550.00 and gave the company an “overweight” rating in a research report on Tuesday, February 7th. Morgan Stanley reduced their price objective on IDEXX Laboratories from $573.00 to $543.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 15th. TheStreet upgraded IDEXX Laboratories from a “c+” rating to a “b-” rating in a research report on Friday, November 25th. Finally, Atlantic Securities increased their price objective on IDEXX Laboratories from $470.00 to $600.00 and gave the company an “overweight” rating in a research report on Tuesday, February 7th.

Insider Buying and Selling

In related news, SVP Kathy V. Turner sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 14th. The stock was sold at an average price of $504.59, for a total transaction of $1,009,180.00. Following the transaction, the senior vice president now directly owns 7,380 shares in the company, valued at approximately $3,723,874.20. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, SVP Kathy V. Turner sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 9th. The stock was sold at an average price of $505.04, for a total value of $505,040.00. Following the completion of the transaction, the senior vice president now owns 6,941 shares in the company, valued at approximately $3,505,482.64. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Kathy V. Turner sold 2,000 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 14th. The shares were sold at an average price of $504.59, for a total value of $1,009,180.00. Following the transaction, the senior vice president now owns 7,380 shares of the company’s stock, valued at approximately $3,723,874.20. The disclosure for this sale can be found here. 2.06% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Altshuler Shaham Ltd purchased a new stake in IDEXX Laboratories during the fourth quarter valued at $26,000. Resurgent Financial Advisors LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at approximately $31,000. Ronald Blue Trust Inc. bought a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at approximately $34,000. Carolinas Wealth Consulting LLC lifted its stake in shares of IDEXX Laboratories by 42.3% in the 2nd quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the company’s stock valued at $35,000 after purchasing an additional 30 shares during the last quarter. Finally, Riverview Trust Co lifted its stake in shares of IDEXX Laboratories by 202.8% in the 3rd quarter. Riverview Trust Co now owns 109 shares of the company’s stock valued at $36,000 after purchasing an additional 73 shares during the last quarter. Hedge funds and other institutional investors own 87.90% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $471.42 on Wednesday. The business’s 50-day moving average price is $479.06 and its two-hundred day moving average price is $413.11. IDEXX Laboratories has a twelve month low of $317.06 and a twelve month high of $560.92. The stock has a market cap of $39.08 billion, a P/E ratio of 58.71, a PEG ratio of 2.64 and a beta of 1.18. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 1.14.

IDEXX Laboratories (NASDAQ:IDXX – Get Rating) last released its quarterly earnings results on Monday, February 6th. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.92 by $0.13. IDEXX Laboratories had a return on equity of 124.51% and a net margin of 20.17%. The firm had revenue of $828.60 million for the quarter, compared to analysts’ expectations of $820.91 million. During the same quarter last year, the firm posted $1.89 EPS. The company’s revenue was up 3.4% compared to the same quarter last year. As a group, equities analysts predict that IDEXX Laboratories will post 9.58 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

(Get Rating)

IDEXX Laboratories, Inc engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other.